Skip to main content

Cannabis Tilray reports fourth-quarter revenue surge, deeper net loss

Tilray founder and CEO Brendan Kennedy poses for a photo before closing the Nasdaq in New York on July 19, 2018, after his company's U.S. IPO.

The Associated Press

Part of cannabis and investing

Cannabis producer Tilray Inc. reported its fourth-quarter revenue surged by more than 200 per cent year-over-year to US$15.5-million, but its net loss for the period also deepened.

The Nanaimo, B.C.-based company said its net loss for the quarter ended Dec. 31, 2018 amounted to US$31 million or 33 US cents a share, compared with a net loss of US$3-million or four US cents a share a year earlier.

Analysts had estimated quarterly revenues of US$14.15-million and a net loss of US$10.43-million or 12 US cents a share, according to those surveyed by Thomson Reuters Eikon.

Story continues below advertisement

Tilray said that the increased net loss for the quarter was primarily due to the increase in operating expenses owing to growth initiatives, expansion of international teams and costs related to financing and merger and acquisition activities.

The company’s average net selling price per gram rose to US$7.52, up from US$7.13 during the same quarter one year earlier.

For the full 2018 financial year, Tilray reported revenue of US$43-million, up 110 per cent from the previous year, and net loss of US$67.7-million compared with US$7.8 million in 2017.

“2018 was a very successful year for Tilray with many corporate milestones,” said Tilray’s chief executive Brendan Kennedy in a statement. “Our team made significant progress on our long-term initiatives including increasing production capacity, expanding and strengthening strategic partnerships, and acquiring complementary businesses to accelerate our future growth and leadership position in medical and adult-use cannabis.”

Available now: Cannabis Professional, the authoritative e-mail newsletter tailored specifically for professionals in the rapidly evolving cannabis industry. Subscribe now.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Discussion loading ...

Cannabis pro newsletter